Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Krelitz Industries

Executive Summary

Service agreement between Krelitz' subsidiary Twin City Wholesale Drug and Voluntary Hospitals of America (VHA) will be "terminated" effective Nov. 30. The VHA agreement generated $45.2 mil. in sales for Krelitz in fiscal 1992 (ended May 2) and accounted for approximately 18% of the company's consolidated sales for the year. Because of the competitive pricing involved in the VHA deal, Krelitz predicted that it "will be able to minimize the impact of the loss of this business" through the reduction in interest rates associated with financing the VHA business and other "actions to reduce costs." Krelitz' FY 1992 sales were already expected to be flat; sales through nine months were off 4.4%. Krelitz also reported that it has reached an agreement in principle in renegotiations on the company's $24 mil. line of bank credit. In addition, Exec VP and Chief Operating Officer Dennis Allingham has left the company.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS021369

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel